Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development
TAIPEI, Feb. 1, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead investor is...